Cargando…

Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy

Murine-based CD19 CAR-T (CD19m CAR-T) therapy can lead to a relatively high CR rate when administered to B-ALL patients for the first time. However, the DOR is sub-optimal and a subset of patients even show primary resistance to CD19m CAR-T. To address these issues, we employed a humanized selective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yu, Zhang, Jianping, Yang, Junfang, Wu, Huantong, Chen, Yao, Li, Nannan, Liu, Zhongfeng, Wang, Xuan, Liu, Weihua, Zhang, Guangji, Zhou, Bin-Bing Stephen, Lu, Peihua, Chen, Zhiguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253302/ https://www.ncbi.nlm.nih.gov/pubmed/35800047 http://dx.doi.org/10.3389/fonc.2022.884782

Ejemplares similares

Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy
por: Wang, Kai, et al.
Publicado: (2020)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
por: Li, Xin, et al.
Publicado: (2021)

Reduced ABO blood group antibody titers in patients after CD19 CAR-T cell therapy
por: Li, Qiang, et al.
Publicado: (2022)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Complications after CD19+ CAR T-Cell Therapy
por: Penack, Olaf, et al.
Publicado: (2020)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation
por: Martínez-Romera, Isabel, et al.
Publicado: (2022)

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2020)

P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
por: Yang, Junfang, et al.
Publicado: (2023)

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
por: Zhang, Cheng, et al.
Publicado: (2020)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

P1389: A NOVEL AND SUCCESSFUL CD7-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR REFRACTORY/RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
por: Zhang, Xian, et al.
Publicado: (2023)

Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant
por: Chen, George, et al.
Publicado: (2022)

High Prevalence of PNH-phenotype Cells in Patients Who Received CD19-targeted CAR T-cell Therapy
por: Yoshihara, Kyoko, et al.
Publicado: (2021)

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
por: Yang, Junfang, et al.
Publicado: (2022)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy
por: Liu, Yanfen, et al.
Publicado: (2018)

MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
por: Jin, Jin, et al.
Publicado: (2023)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.
por: Frank, Matthew J., et al.
Publicado: (2023)

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
por: Ho, Jin-Yuan, et al.
Publicado: (2021)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
por: Nie, Yuru, et al.
Publicado: (2020)

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
por: Hsieh, Emily M., et al.
Publicado: (2022)

Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
por: Xing, Limin, et al.
Publicado: (2021)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

Delay in COVID-19 Presentation in Patients Recently Treated with CD-19 Directed CAR-T Therapy
por: Wuliji, Natalie, et al.
Publicado: (2022)

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
por: Zhang, Yu, et al.
Publicado: (2022)

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma
por: Quintás-Cardama, Alfonso
Publicado: (2018)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
por: Chen, Gregory M., et al.
Publicado: (2023)

Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL
por: Zhang, Qiong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vajc3t1kmgm5m0jofrljtmiio8